Menopause and dry eye are connected, and the obvious explanation — oestrogen falls, eyes get dry, replacing oestrogen should help — turns out to be wrong in an instructive way.
A study of more than 25,000 women found hormone therapy associated with more dry eye, not less.
How common
Estimates vary considerably, which is worth stating up front.
One source reports dry eye in up to 38% of postmenopausal women compared with about 20% of premenopausal women[2]. Another puts the figure at around 61% of perimenopausal and menopausal women[6].
That’s a wide spread, reflecting different definitions and populations. What’s consistent across sources is the direction: greater prevalence in women than men, and greater after menopause than before[1].
Where hormones act
Tears have three layers, and hormones reach all of them.
The lipid (oil) layer comes from the meibomian glands along the eyelids. These glands contain both oestrogen and androgen receptors[2][5], making them directly sensitive to hormonal change. When the oil layer thins, tears evaporate faster than they can be replaced.
The aqueous (watery) layer comes from the lacrimal glands, which are also influenced by androgens[5].
The mucin layer involves conjunctival goblet cells, likewise affected by sex hormones[1].
Receptors have been identified across the ocular surface — conjunctiva, cornea and meibomian glands[6].
The evaporative route is described as the primary driver of dry eye symptoms during menopause[5]. Which points attention at the oil layer specifically.
The hormone therapy paradox
Here is the finding that reframes the topic.
The Women’s Health Study followed more than 25,000 postmenopausal women. Hormone therapy use was associated with a higher risk of developing dry eye[5].
- Oestrogen alone: 69% greater risk compared with no hormone therapy[5]
- Each additional three years of use: approximately 15% increase in risk of clinically diagnosed dry eye or severe symptoms[5]
And combined oestrogen-progesterone therapy carried lower risk than oestrogen alone[5].
A separate review reaches a consistent conclusion: postmenopausal hormone therapy has shown limited benefit for dry eye symptoms and may even result in progression of meibomian gland dysfunction, decreased tear break-up time, and reduced tear flow[6].
To be clear about scope: this is not an argument for or against hormone therapy, which is prescribed for reasons well beyond ocular comfort and involves a much broader risk-benefit assessment. It is a finding about one specific outcome.
Why oestrogen doesn’t help
The mechanism explains the paradox, and it involves androgens more than oestrogen.
Oestrogen inhibits lipid synthesis in the meibomian gland, promoting meibomian gland dysfunction and therefore evaporative dry eye[1]. That’s the opposite of what the intuitive model predicts.
More specifically, oestrogen appears to act on these glands indirectly — by antagonising androgen, blocking its uptake or its conversion to the more potent form DHT[1].
Which leads to a reframing of the whole question:
The high prevalence of dry eye among women may not be due to increased action of oestrogen, but to decreased action of androgen[1].
Androgens decline at menopause too, and they’re the hormone the meibomian and lacrimal glands appear to depend on. Low androgen levels are described as a more consistent factor in dry eye aetiology than oestrogen[6].
Adding oestrogen therefore doesn’t restore what was lost. It may further suppress what remains.
A bit more detail — on why the picture isn’t fully settled. Oestrogen’s effect appears dose-dependent and directionally opposite at different levels: at low doses it seems to promote gland cell survival and protect against exocrine gland inflammation, while high levels can increase inflammation[3]. Lacrimal gland deficiency has been observed after menopause, after ovariectomy, and in women taking oral contraceptives — despite variable oestrogen levels in those states[3]. So oestrogen alone doesn’t explain the pattern.
What remains genuinely unsettled
The honest summary from the literature is that this isn’t resolved.
A review in *Gynecological Endocrinology* states that it remains controversial whether oestrogen or androgen deficiency, or their imbalance, impairs ocular surface function[4]. And on treatment, the scientific literature stands between a therapeutic and a promoting effect of hormone therapy on eye dryness[4].
So: androgen decline is the better-supported explanation, hormone therapy is associated with worse rather than better outcomes on this measure, and the underlying balance question isn’t closed.
What this means practically
Three implications follow.
Dry eye deserves its own assessment, not attribution to menopause. The evaporative and aqueous-deficient types respond to different treatments, and an ophthalmologist can distinguish them. “It’s my age” is a conclusion that skips the diagnostic step.
Don’t expect hormone therapy to resolve it, and if you’re on hormone therapy and dry eye developed or worsened, that’s worth mentioning to whoever prescribed it — as information rather than a reason to stop.
Supplements aren’t the first move here either. As covered in the omega-3 post, the DREAM trial found no significant difference between omega-3 and an olive oil placebo across a year — and both groups improved substantially, which is its own lesson about attributing improvement.
One clinical note worth adding: since meibomian gland dysfunction is the primary evaporative driver, treatments targeting the eyelids and oil layer are the ones aimed at the actual mechanism. That’s a conversation with an eye clinician rather than a shelf decision.
Closing
The intuitive chain — oestrogen falls, eyes dry, replace oestrogen — fails at the last link, and fails in the direction that matters.
Oestrogen-only therapy was associated with 69% greater dry eye risk in a study of 25,000 women. The mechanism suggests why: oestrogen suppresses meibomian lipid synthesis and antagonises androgen, and androgen is the hormone those glands appear to need.
What I’d underestimated was how often “hormone declines, so replace the hormone” gets applied without checking which hormone the tissue in question actually depends on. Here it depends on a different one.
Which makes the practical advice unusually clear despite the unsettled science: have the eyes assessed on their own terms rather than filed under menopause.
At a Glance
- Prevalence estimates range widely — up to 38% postmenopausal versus about 20% premenopausal in one source, around 61% of peri- and menopausal women in another
- Meibomian glands carry both oestrogen and androgen receptors; the lacrimal glands are androgen-influenced
- The evaporative route — a thinned oil layer — is the primary driver
- Women’s Health Study, 25,000+ women: hormone therapy associated with higher dry eye risk
- Oestrogen alone: 69% greater risk; each additional three years ≈ 15% increase
- Oestrogen inhibits meibomian lipid synthesis and antagonises androgen uptake and conversion to DHT
- Low androgen is described as the more consistent factor in aetiology
- Whether oestrogen deficiency, androgen deficiency or their imbalance is responsible remains controversial
※ This article is for general information and does not replace medical advice, diagnosis or treatment. Nothing here is a recommendation for or against hormone therapy — that decision involves considerations far beyond ocular comfort and belongs with your clinician. Do not start or stop prescribed medication on your own. Persistent eye discomfort, redness, pain or vision change warrants examination by an ophthalmologist.
References
- “Sex hormones and dry eye disease: Current update”, IP International Journal of Ocular Oncology and Oculoplasty (oestrogen’s inhibition of meibomian lipid synthesis; androgen antagonism), https://ijooo.org/archive/volume/7/issue/2/article/6961
- “The Estrogen-Eye Connection: Managing Dry Eyes During Menopause” (prevalence figures; receptor distribution), Doctronic, https://www.doctronic.ai/blog/the-estrogen-eye-connection-managing-dry-eyes-during-menopause/
- “Expression of Androgen and Estrogen Receptors in the Human Lacrimal Gland”, PMC (dose-dependent oestrogen effects; lacrimal deficiency across differing oestrogen states), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053362/
- “Menopause and dry eye. A possible relationship”, Gynecological Endocrinology 2005;20(5), https://www.tandfonline.com/doi/abs/10.1080/09513590400027257
- “Menopause and Dry Eye Treatment Guide”, Greenwich Eye (Women’s Health Study figures; three-layer mechanism), https://greenwicheye.com/article/menopause-and-dry-eye-treatment-guide/
- “Dry Eye Disease in Postmenopausal Women”, Ophthalmology Breaking News (androgen as more consistent factor; hormone therapy and MGD progression), https://ophthalmologybreakingnews.com/postmenopausal-women—dry-eye-disease–estradiol-drops-